Skip to main content
Published Online:https://doi.org/10.3928/01477447-20120822-01
First page image

  • 1.Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998; 91(1):3–21.

    Crossref MedlineGoogle Scholar
  • 2.Landis SH, Murray T, Bolden S, et al.Cancer statistics. CA Cancer J Clin. 1998; 48(1):6–29.10.3322/canjclin.48.1.6

    Crossref MedlineGoogle Scholar
  • 3.Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006; 42(11):1539–1543.10.1016/j.ejca.2005.11.037

    Crossref MedlineGoogle Scholar
  • 4.Selvanayagam P, Alexanian R. Plasma cell myeloma—new biological insights and advances in therapy. Blood. 1989; 73(4):865–879.

    Crossref MedlineGoogle Scholar
  • 5.Niesvizky R, Warrell RP. Pathophysiology and management of bone disease in multiple myeloma. Cancer Invest. 1997; 15(1):85–90.10.3109/07357909709018921

    Crossref MedlineGoogle Scholar
  • 6.Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992; 6(2):323–346.

    Crossref MedlineGoogle Scholar
  • 7.Kyle RA, Gertz MA, Witzig TE, et al.Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21–33.10.4065/78.1.21

    Crossref MedlineGoogle Scholar
  • 8.Sawyer JR, Waldron JA, Jagannath S, et al.Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995; 82(1):41–49.10.1016/0165-4608(94)00284-I

    Crossref MedlineGoogle Scholar
  • 9.Fechtner K, Hillengass J, Delorme S, et al.Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology. 2010; 257(1):195–204.10.1148/radiol.10091809

    Crossref MedlineGoogle Scholar
  • 10.Dimopoulos MA, Kastritis E, Michalis E, et al.The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function. Ann Oncol. 2012; 23:722–729.10.1093/annonc/mdr276

    Crossref MedlineGoogle Scholar
  • 11.Collins C. Multiple myeloma. In: , Husband JE, Resnik RH, eds. Imaging of Oncology. 3rd ed. Essex, United Kingdom: Informa UK Ltd; 2010:851–869.

    Google Scholar
  • 12.Dinter DJ, Neff WK, Klaus J, et al.Comparison of whole-body MR imaging and conventional x-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol. 2009; 88(5):457–464.10.1007/s00277-008-0621-6

    Crossref MedlineGoogle Scholar
  • 13.Mahnken AH, Wildberger JE, Gehbauer G, et al.Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol. 2002; 178(6):1429–1436.

    Crossref MedlineGoogle Scholar
  • 14.Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol. 2005; 55(1):56–63.10.1016/j.ejrad.2005.01.017

    Crossref MedlineGoogle Scholar
  • 15.Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol. 2011; 196(6):W790–W795.10.2214/AJR.10.5979

    Crossref MedlineGoogle Scholar
  • 16.Sommer G, Klarhöfer M, Lenz C, Scheffler K, Bongartz G, Winter L. Signal characteristics of focal bone marrow lesions in patients with multiple myeloma using whole body T1w-TSE, T2w-STIR and diffusion-weighted imaging with background suppression. Eur Radiol. 2011; 21:857–862.10.1007/s00330-010-1950-0

    Crossref MedlineGoogle Scholar
  • 17.Lütje S, de Rooy JW, Croockewit S. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol. 2009; 88(12):1161–1168.10.1007/s00277-009-0829-0

    Crossref MedlineGoogle Scholar
  • 18.Shortt CP, Gleeson TG, Breen KA. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009; 192(4):980–986.10.2214/AJR.08.1633

    Crossref MedlineGoogle Scholar
  • 19.Sacchi S, Marcheselli R, Lazzaro A, et al.A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leuk Lymphoma. 2011; 52(10):1942–1948.10.3109/10428194.2011.584006

    Crossref MedlineGoogle Scholar
  • 20.Richardson PG, Weller E, Lonial S, et al.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010; 116(5):679–686.10.1182/blood-2010-02-268862

    Crossref MedlineGoogle Scholar
  • 21.Ahn JS, Yang DH, Jung SH, et al.A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma. Ann Hematol. 2012; 91(7):1023–1030.10.1007/s00277-012-1420-7

    Crossref MedlineGoogle Scholar
  • 22.Hutchison CA, Bradwell AR, Cook M. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cutoff hemodialysis. Clin J Am Soc Nephrol. 2009; 4(4):745–754.10.2215/CJN.04590908

    Crossref MedlineGoogle Scholar
  • 23.Facon T, Mary JY, Pégourie B, et al.Dexamethasone-based regimens versus melphalanprednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006; 107(4):1292–2198.10.1182/blood-2005-04-1588

    Crossref MedlineGoogle Scholar
  • 24.Terpos E. Bisphosphonate anticancer activity in multiple myeloma. Anticancer Agents Med Chem. 2012; 12(2):129–136.

    Crossref MedlineGoogle Scholar
  • 25.Oken MM, Pomeroy C, Weisdorf D. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996; 100(6):624–628.10.1016/S0002-9343(95)00043-7

    Crossref MedlineGoogle Scholar
  • 26.Chang SA, Lee SS, Ueng SW, Yuan LJ, Shih CH. Surgical treatment for pathological long bone fracture in patients with multiple myeloma: a retrospective analysis of 22 cases. Chang Gung Med J. 2001; 24(5):300–306.

    MedlineGoogle Scholar
  • 27.Hrabálek L, Bacovský J, Scudla V, Wamek T, Kalita O. Multiple spinal myeloma and its surgical management. Rozhl Chir. 2011; 90(5):270–276.

    MedlineGoogle Scholar
  • 28.Pflugmacher R, Schulz A, Schroeder RJ, Schaser KD, Klostermann CK, Melcher I. A prospective two-year follow-up of thoracic and lumbar osteolytic vertebral fractures caused by multiple myeloma treated with balloon kyphoplasty. Z Orthop Ihre Grenzgeb. 2007; 145(1):39–47.10.1055/s-2007-960502

    Crossref MedlineGoogle Scholar

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×